Triptan nonresponders: Do they exist and who are they?

Michele Viana, Armando A. Genazzani, Salvatore Terrazzino, Giuseppe Nappi, Peter J. Goadsby

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Triptans represent the best treatment option for most migraine attacks, although this is not as well studied as it might be in controlled trials. Their efficacy and tolerability vary, both between agents, and from patient to patient, with about 30%-40% of patients not responding adequately to therapy. As yet unexplained, the failure of one triptan does not predict failure with another, and therefore triptan nonresponders cannot be defined as individuals who have failed a single triptan. Five clinical studies provide evidence that switching from a triptan that is ineffective to a second one can result in effective treatment in a proportion of patients. Systematic studies investigating whether there are patients who do not respond to all triptans in all formulations are lacking. Methods: Here we discuss the importance of identifying triptan nonresponders, the literature supporting their existence, and the issues to be resolved to design trials to investigate this. Conclusion: So far, no scientific data about the presence of a triptan nonresponder population are available.We propose a pragmatic study design to assess the existence of this subpopulation, recognizing the complexity of the question and the likelihood that more than one issue is at play in nonresponders.

Original languageEnglish
Pages (from-to)891-896
Number of pages6
JournalCephalalgia
Volume33
Issue number11
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Tryptamines
Proxy
Migraine Disorders
Therapeutics

Keywords

  • migraine
  • nonresponder
  • population
  • predictor
  • responder
  • Triptan

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Viana, M., Genazzani, A. A., Terrazzino, S., Nappi, G., & Goadsby, P. J. (2013). Triptan nonresponders: Do they exist and who are they? Cephalalgia, 33(11), 891-896. https://doi.org/10.1177/0333102413480756

Triptan nonresponders : Do they exist and who are they? / Viana, Michele; Genazzani, Armando A.; Terrazzino, Salvatore; Nappi, Giuseppe; Goadsby, Peter J.

In: Cephalalgia, Vol. 33, No. 11, 08.2013, p. 891-896.

Research output: Contribution to journalArticle

Viana, M, Genazzani, AA, Terrazzino, S, Nappi, G & Goadsby, PJ 2013, 'Triptan nonresponders: Do they exist and who are they?', Cephalalgia, vol. 33, no. 11, pp. 891-896. https://doi.org/10.1177/0333102413480756
Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: Do they exist and who are they? Cephalalgia. 2013 Aug;33(11):891-896. https://doi.org/10.1177/0333102413480756
Viana, Michele ; Genazzani, Armando A. ; Terrazzino, Salvatore ; Nappi, Giuseppe ; Goadsby, Peter J. / Triptan nonresponders : Do they exist and who are they?. In: Cephalalgia. 2013 ; Vol. 33, No. 11. pp. 891-896.
@article{a2881b115f7a4ad2bf668c0fd8e99b6b,
title = "Triptan nonresponders: Do they exist and who are they?",
abstract = "Background: Triptans represent the best treatment option for most migraine attacks, although this is not as well studied as it might be in controlled trials. Their efficacy and tolerability vary, both between agents, and from patient to patient, with about 30{\%}-40{\%} of patients not responding adequately to therapy. As yet unexplained, the failure of one triptan does not predict failure with another, and therefore triptan nonresponders cannot be defined as individuals who have failed a single triptan. Five clinical studies provide evidence that switching from a triptan that is ineffective to a second one can result in effective treatment in a proportion of patients. Systematic studies investigating whether there are patients who do not respond to all triptans in all formulations are lacking. Methods: Here we discuss the importance of identifying triptan nonresponders, the literature supporting their existence, and the issues to be resolved to design trials to investigate this. Conclusion: So far, no scientific data about the presence of a triptan nonresponder population are available.We propose a pragmatic study design to assess the existence of this subpopulation, recognizing the complexity of the question and the likelihood that more than one issue is at play in nonresponders.",
keywords = "migraine, nonresponder, population, predictor, responder, Triptan",
author = "Michele Viana and Genazzani, {Armando A.} and Salvatore Terrazzino and Giuseppe Nappi and Goadsby, {Peter J.}",
year = "2013",
month = "8",
doi = "10.1177/0333102413480756",
language = "English",
volume = "33",
pages = "891--896",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "11",

}

TY - JOUR

T1 - Triptan nonresponders

T2 - Do they exist and who are they?

AU - Viana, Michele

AU - Genazzani, Armando A.

AU - Terrazzino, Salvatore

AU - Nappi, Giuseppe

AU - Goadsby, Peter J.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Triptans represent the best treatment option for most migraine attacks, although this is not as well studied as it might be in controlled trials. Their efficacy and tolerability vary, both between agents, and from patient to patient, with about 30%-40% of patients not responding adequately to therapy. As yet unexplained, the failure of one triptan does not predict failure with another, and therefore triptan nonresponders cannot be defined as individuals who have failed a single triptan. Five clinical studies provide evidence that switching from a triptan that is ineffective to a second one can result in effective treatment in a proportion of patients. Systematic studies investigating whether there are patients who do not respond to all triptans in all formulations are lacking. Methods: Here we discuss the importance of identifying triptan nonresponders, the literature supporting their existence, and the issues to be resolved to design trials to investigate this. Conclusion: So far, no scientific data about the presence of a triptan nonresponder population are available.We propose a pragmatic study design to assess the existence of this subpopulation, recognizing the complexity of the question and the likelihood that more than one issue is at play in nonresponders.

AB - Background: Triptans represent the best treatment option for most migraine attacks, although this is not as well studied as it might be in controlled trials. Their efficacy and tolerability vary, both between agents, and from patient to patient, with about 30%-40% of patients not responding adequately to therapy. As yet unexplained, the failure of one triptan does not predict failure with another, and therefore triptan nonresponders cannot be defined as individuals who have failed a single triptan. Five clinical studies provide evidence that switching from a triptan that is ineffective to a second one can result in effective treatment in a proportion of patients. Systematic studies investigating whether there are patients who do not respond to all triptans in all formulations are lacking. Methods: Here we discuss the importance of identifying triptan nonresponders, the literature supporting their existence, and the issues to be resolved to design trials to investigate this. Conclusion: So far, no scientific data about the presence of a triptan nonresponder population are available.We propose a pragmatic study design to assess the existence of this subpopulation, recognizing the complexity of the question and the likelihood that more than one issue is at play in nonresponders.

KW - migraine

KW - nonresponder

KW - population

KW - predictor

KW - responder

KW - Triptan

UR - http://www.scopus.com/inward/record.url?scp=84879979228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879979228&partnerID=8YFLogxK

U2 - 10.1177/0333102413480756

DO - 10.1177/0333102413480756

M3 - Article

C2 - 23564209

AN - SCOPUS:84879979228

VL - 33

SP - 891

EP - 896

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 11

ER -